EP
Highly rated in
22
conditions
Highly rated in
22
conditions
Check Dr. Edward L. Pan's experience treating your condition:
About Dr. Edward L. Pan

Edward Pan is a Neurologist in Dallas, Texas. Pan has been practicing medicine for over 27 years and is highly rated in 22 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, and Brain Tumor. He is licensed to treat patients in Florida and Texas. Pan is currently accepting new patients.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 17 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Edward L. Pan it is best to call his office and ask if your insurance is accepted.


Dr. Edward L. Pan accepts the following insurance:

  •  Ambetter

Call to see if your plan is accepted.
Locations
2201 Inwood Rd, 3rd Floor, Suite 500, Dallas, TX 75390
Background & Education
Graduate Institution
Boston University School Of Medicine, 1996
Specialties
Neurology
Licenses
Psychiatry & Neurology in FL
Hospital Affiliations
William P Clements Jr University Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Genomically-Guided Treatment Trial in Brain Metastases
Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
A Single Arm Pilot Study of Intrathecally Administered DepoCyt® With Systemic Sorafenib in the Treatment of Neoplastic Meningitis From Solid Tumors
Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II Study of Irinotecan HCI in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
View 11 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors